

**Clopidogrel plus Aspirin Use is Associated with Worse Long-Term Outcomes, but Aspirin Use Alone is Safe in Patients with Vasospastic Angina: Results from the VA-Korea Registry, A Prospective Multi-Center Cohort.**

Seong-Sik Cho, MD<sup>a</sup>; Sang-Ho Jo, MD<sup>b\*</sup>; Seung Hwan Han, MD<sup>c</sup>; Kwan Yong Lee, MD<sup>d</sup>; Sung-Ho Her, MD<sup>e</sup>; Min-Ho Lee, MD<sup>f</sup>; Won-Woo Seo, MD<sup>g</sup>; Sung Eun Kim, MD<sup>g</sup>; Tae-Hyun Yang, MD<sup>h</sup>; Keun-Ho Park, MD<sup>i</sup>; Jung-Won Suh, MD<sup>j</sup>; Byoung-Kwon Lee, MD<sup>k</sup>; Seung-Woon, Rha, MD<sup>l</sup>; Hyeyon-Cheol Gwon, MD<sup>m</sup>; Sang Hong Baek, MD<sup>n</sup>

<sup>a</sup>Department of Occupational and Environmental Medicine, College of Medicine, Dong-A University, Busan, Korea

<sup>b\*</sup>Division of Cardiology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, Korea

<sup>c</sup>Department of Cardiovascular Medicine, Gil Medical Center, Gachon University, Incheon,

<sup>d</sup> Department of Cardiovascular Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, South Korea

<sup>e</sup>Department of Cardiovascular Medicine, Daejeon St. Mary's Hospital, The Catholic University of Korea, Daejeon, South Korea

<sup>f</sup>Department of Cardiovascular Medicine, Soonchunhyang Seoul Hospital, Seoul, South Korea

<sup>g</sup>Department of Cardiovascular Medicine Hallym University Kangdong Hospital, Seoul, South Korea

<sup>h</sup>Department of Cardiovascular Medicine, Busan Paik Hospital, Inje University, Busan, South Korea

<sup>i</sup>Department of Cardiovascular Medicine, Chosun Medical Center, Gwangju, South Korea

<sup>j</sup>Department of Cardiovascular Medicine, Bundang Hospital, Seoul National University,

Seongnam, South Korea

<sup>k</sup>Department of Cardiovascular Medicine, Gangnam Severance Hospital, Yonsei University, Seoul, South Korea

<sup>l</sup>Department of Cardiovascular Medicine, Guro Hospital, Korea University, Seoul, South Korea

<sup>m</sup>Department of Cardiovascular Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea

<sup>n</sup>Department of Cardiovascular Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

**Supplementary table 1. result of Cox proportional hazard regression for primary outcome additionally including atherosclerosis and troponin-I in the model (n=937)**

	HR	95%CI	p
Age	1.00	0.98	1.02
Female	0.98	0.56	1.73
History of CHD	1.04	0.53	2.04
Smoking	1.20	0.69	2.10
Hypertension	0.86	0.50	1.48
DM	0.94	0.40	2.23
Dyslipidemia	1.75	1.01	3.05
Calcium Channel blocker	1.36	0.83	2.23
Definite spasm	1.12	0.45	2.81
Atherosclerosis ≥ 50%	1.07	0.44	2.59
Troponin-I	1.03	1.00	1.06
<b>Antiplatelet agents</b>			
No antiplatelet agent	reference		
Aspirin	0.83	0.48	1.45
Clopidogrel	0.50	0.12	2.11
Aspirin + clopidogrel	1.84	0.89	3.79

HR: Hazard ratio, CI: confidence interval, CHD: Coronary heart disease, DM: diabetes mellitus, primary outcome includes arrhythmia, acute coronary syndrome, and death

**Supplementary table 2. result of Cox proportional hazard regression for primary outcome additionally including atherosclerosis and troponin-I in the model among patients without history of PCI (n= 912)**

	HR	95%CI		p
Age	0.99	0.97	1.02	0.636
Female	0.92	0.51	1.65	0.781
History of CHD	0.80	0.34	1.89	0.610
Smoking	1.04	0.58	1.86	0.901
Hypertension	0.95	0.54	1.66	0.854
DM	1.12	0.47	2.64	0.804
Dyslipidemia	1.71	0.97	3.04	0.066
Calcium Channel blocker	1.06	0.42	2.66	0.908
Definite spasm	1.29	0.77	2.17	0.337
Atherosclerosis ≥ 50%	0.84	0.29	2.41	0.740
Troponin-I	1.02	0.99	1.06	0.209
<b>Antiplatelet agents</b>				
No antiplatelet agent	reference			
Aspirin	0.89	0.51	1.56	0.682
Clopidogrel	0.54	0.13	2.28	0.399
Aspirin + clopidogrel	1.65	0.71	3.84	0.243

PCI: percutaneous coronary intervention, HR: Hazard ratio, CI: confidence interval, CHD: Coronary heart disease, DM: diabetes mellitus, primary outcome includes arrhythmia, acute coronary syndrome, and death

## Supplementary Figure

